Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 6, 2019

Open-Label Phase 2 Clinical Trial of ManNAc for GNE Myopathy (S23.008)

Nuria Carrillo, Marjan Huizing, Petcharat Leoyklang, Melanie Quintana, Joseph Shrader, Kennan Bradley, Christina Slota, John Perreault, Bradley Class, Carla Ciccone, Rebecca Parks, Galen Joe, John Heiss, Scott Berry, May Christine Malicdan, William Gahl
First published April 16, 2019,
Nuria Carrillo
1NHGRI Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjan Huizing
1NHGRI Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petcharat Leoyklang
1NHGRI Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Quintana
5Berry Consultants Austin TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Shrader
2Rehabilitation Medicine Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kennan Bradley
1NHGRI Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Slota
6RTI Health Solutions Research Triangle Park NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Perreault
3NICHD Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley Class
1NHGRI Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla Ciccone
1NHGRI Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Parks
2Rehabilitation Medicine Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Galen Joe
2Rehabilitation Medicine Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Heiss
4NINDS, NIH Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Berry
5Berry Consultants Austin TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
May Christine Malicdan
1NHGRI Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Gahl
1NHGRI Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Open-Label Phase 2 Clinical Trial of ManNAc for GNE Myopathy (S23.008)
Nuria Carrillo, Marjan Huizing, Petcharat Leoyklang, Melanie Quintana, Joseph Shrader, Kennan Bradley, Christina Slota, John Perreault, Bradley Class, Carla Ciccone, Rebecca Parks, Galen Joe, John Heiss, Scott Berry, May Christine Malicdan, William Gahl
Neurology Apr 2019, 92 (15 Supplement) S23.008;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Assess long-term safety, tolerability, pharmacokinetics, and biochemical effect of ManNAc in subjects with GNE myopathy and identify clinical endpoints suitable for subsequent clinical trials.

Background: GNE myopathy is a rare, autosomal recessive myopathy caused by mutations in GNE, the gene encoding the rate-limiting enzyme in sialic acid biosynthesis. The disease manifests as an adult-onset myopathy characterized by progressive skeletal muscle weakness and atrophy. There is no approved therapy for this disease. Hyposialylation of muscle glycoproteins mediates the pathophysiology of the disease. ManNAc, an uncharged monosaccharide and the first committed precursor in sialic acid biosynthesis, is an oral therapeutic candidate that prevents muscle weakness in the mouse model of GNE myopathy. A first-in-human, randomized, placebo-controlled, double-blind, single-ascending dose study (NCT01634750) showed ManNAc is safe and restored sialic acid production in GNE myopathy patients.

Design/Methods: A Phase 2, open-label, single-center study (NCT02346461) enrolled twelve subjects with genetically-confirmed GNE myopathy. Subjects received oral ManNAc at 6 grams twice daily (12 grams/day) and were evaluated at baseline, 3, 6, 12, 18, 24 and 30 months.

Results: Long-term administration of ManNAc at 6 grams twice daily is safe but was associated with decreased gastrointestinal tolerability. ManNAc resulted in a sustained increase in levels of plasma free sialic acid (Neu5Ac). Comparison of serial-sampled plasma ManNAc and Neu5Ac at 6 grams BID and 4 grams TID daily showed increased bioavailability with TID dosing. Biochemical efficacy was assessed by increase in muscle sialylation after 3 months of ManNAc administration. Measures of muscle strength (including quantitative muscle assessment), function, and patient-reported outcomes were evaluated for suitability to test clinical efficacy in future trials.

Conclusions: The findings of this study support further development of ManNAc as a therapy for GNE myopathy. A multicenter, randomized, placebo-controlled, double-blind trial of ManNAc in subjects with GNE myopathy is planned.

Disclosure: Dr. Carillo-Carrasco has received research support from Leadiant Biosciences. Dr. Huizing has received compensation for serving on the Board of Directors of Leadiant. Dr. Huizing has received royalty, license fees, or contractual rights payments from Leadiant. Dr. Leoyklang has nothing to disclose. Dr. Quintana has nothing to disclose. Dr. Shrader has nothing to disclose. Dr. Bradley has nothing to disclose. Dr. Slota has nothing to disclose. Dr. Perreault has nothing to disclose. Dr. Class has nothing to disclose. Dr. Ciccone has nothing to disclose. Dr. Parks has nothing to disclose. Dr. Joe has nothing to disclose. Dr. Heiss has nothing to disclose. Dr. Berry has nothing to disclose. Dr. Malicdan has received royalty, license fees, or contractual rights payments from Leadiant Biosciences. Dr. Malicdan has received research support from Leadiant Biosciences. Dr. Gahl has received royalty, license fees, or contractual rights payments from Leadiant Biosciences. Dr. Gahl has received research support from Leadiant Biosciences.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder

Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise